
|Videos|March 22, 2017
Scrutiny Continues to Grow Around the Cost of Specialty Drugs
Author(s)Lauren Santye, Assistant Editor
Marc O'Connor, COO and chief strategy officer of Curant Health, discusses increased oversight of specialty medication pricing.
Advertisement
Marc O'Connor, COO and chief strategy officer of Curant Health, discusses increased oversight of specialty medication pricing.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Key Data, Interviews at the 2025 ASH Annual Meeting and Exposition
2
Guiding Patients With Sickle Cell Disease Through the Transformative Era of Gene Therapy
3
New Data Highlights Pharmacists’ Expanding Roles in Hematologic Malignancies
4
Bridging Response Emerges as Key Predictor of Cilta-Cel Outcomes in CARTITUDE-4
5

















































































































































































































